ArticleGastroenterology and hepatology from bed to bench2026
Long-term effects of human development on the global burden of gallbladder and biliary tract cancer: a longitudinal multilevel analysis, 1990-2021.
Article in Gastroenterology and hepatology from bed to bench, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To evaluate the longitudinal effect of human development on the global burden of gallbladder and biliary tract cancers (GBTC) from 1990 to 2021. Background: GBTCs are rare but highly fatal malignancies with substantial geographic heterogeneities in incidence and mortality. Socioeconomic development, quantified through Human Development Index (HDI), may influence GBTC burden, but its long-term impact has not been quantified using longitudinal data. Methods: This ecological study analyzed Global Burden of Disease (GBD) 2021 estimates across 204 countries. Four age-standardized indicators were examined, incidence rate (ASIR), mortality rate (ASMR), years-of-life-lost rate (ASYLLR), and mortality-to-incidence ratio (MIR). Temporal trends and HDI effects were evaluated using a longitudinal multilevel Gamma generalized linear mixed model (GLMM) to account for regional clustering and global heterogeneity. Results: Between 1990 and 2021, all four indicators declined in both development groups, with steeper reductions in more-developed countries. The ASMR and ASYLLR were initially higher in high-HDI regions but declined more rapidly, crossing below less-developed regions in the early 2000s. MIR showed a delayed but sharper decrease, falling below 1 in more-developed settings around 2010, while remaining above 1 in less-developed areas. The longitudinal GLMM confirmed significant HDI-time interactions (p < 0.001), indicating faster burden reduction with higher development levels. Conclusion: Human development is strongly associated with accelerated declines in GBTC incidence, mortality, and fatal burden. The results highlight the critical role of socioeconomic progress, healthcare infrastructure, and early detection in reducing disparities, underscoring the importance of targeted investments in low- and middle-HDI countries to achieve more equitable global cancer control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.